Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Huntingtin silencing delays onset and slows progression of Huntington’s disease: a biomarker study

27 Mar 2021

Abstract excerpt

Huntington's disease is a dominantly inherited, fatal neurodegenerative disorder caused by a CAG expansion in the huntingtin (HTT) gene, coding for pathological mutant HTT protein (mHTT). Because of its gain-of-function mechanism and monogenic aetiology, strategies to lower HTT are being actively investigated as disease-modifying therapies. Most approaches are currently targeted at the manifest stage, where...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34043007
DOI: 10.1093/brain/awab190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Huntingtin silencing delays onset and slows progression of Huntington’s disease: a biomarker studyPMID 34043007Read ↗

<i>HTT</i> silencing delays onset and slows progression of Huntington’s disease like phenotype: Monitoring with a novel neurovascular biomarkerSemantic proximity Read ↗

Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.Semantic proximity Read ↗

Shared and disease-specific human brain vascular signatures in Alzheimer’s disease, frontotemporal dementia, and Huntington’s diseaseSemantic proximity Read ↗

Characterizing spatiotemporal white matter hyperintensity pathophysiology in vivo to disentangle vascular and neurodegenerative contributionsSemantic proximity Read ↗

Multimodal characterization of age-dependent neurovascular phenotypes in Notch3R170C CADASIL mice by ultra-high-field MRI and histological analyses.Semantic proximity Read ↗

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary ReviewSemantic proximity Read ↗

Timing of selective basal ganglia white matter loss in Huntington’s diseaseSemantic proximity Read ↗

Vascular dysfunction in Huntington’s disease is located at the blood-CSF barrier and is rescued by sphingosine-1-phosphate receptor agonistSemantic proximity Read ↗

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease.Semantic proximity Read ↗

Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease.Semantic proximity Read ↗

Huntingtonʼs diseaseSemantic proximity Read ↗

Molecular Imaging of Huntington's Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.